Patents by Inventor Denise L. Faustman
Denise L. Faustman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8187886Abstract: The invention relates to methods of isolating white blood cells (WBCs) from a sample, e.g., whole blood, using magnetic particles that specifically bind to WBCs and a series of specific steps and conditions. The methods can include one or more of decreasing the viscosity of the sample prior to WBC isolation, agitating the sample at specified frequencies, and/or using a sample container arranged such that all of the sample is placed in close proximity (e.g., within 5, 2, 1, or 0.5 mm) to the source of the magnetic field. The new methods provide for isolation of WBC preparations with high yield, purity, and viability. The methods are designed for compatibility with automation protocols for rapid processing of multiple samples.Type: GrantFiled: January 10, 2011Date of Patent: May 29, 2012Assignee: The General Hospital CorporationInventors: Denise L. Faustman, Douglas E. Burger
-
Patent number: 8021693Abstract: The invention features methods for increasing or maintaining the number of functional cells of a predetermined type in a mammal (e.g., a human patient), for example, the insulin producing cells of the pancreas, liver cells, spleen cells, or bone cells, that has injured or damaged cells of the predetermined type or is deficient in cells of the predetermined type.Type: GrantFiled: August 28, 2009Date of Patent: September 20, 2011Assignee: The General Hospital CorporationInventor: Denise L. Faustman
-
Publication number: 20110177592Abstract: An apparatus for magnetically separating constituents of blood includes: a first portion having a solid support haying fixedly attached thereon a plurality of ring magnets, each ring magnet defining an interior perimeter enclosing an aperture; and a second portion removably attached to the first portion, wherein the second portion includes a solid substrate having surfaces defining a plurality of second apertures, each second aperture configured to removably hold a vial.Type: ApplicationFiled: July 13, 2009Publication date: July 21, 2011Inventors: Denise L. Faustman, Douglas E. Burger
-
Publication number: 20110111476Abstract: The invention relates to methods of isolating white blood cells (WBCs) from a sample, e.g., whole blood, using magnetic particles that specifically bind to WBCs and a series of specific steps and conditions. The methods can include one or more of decreasing the viscosity of the sample prior to WBC isolation, agitating the sample at specified frequencies, and/or using a sample container arranged such that all of the sample is placed in close proximity (e.g., within 5, 2, 1, or 0.5 mm) to the source of the magnetic field. The new methods provide for isolation of WBC preparations with high yield, purity, and viability. The methods are designed for compatibility with automation protocols for rapid processing of multiple samples.Type: ApplicationFiled: January 10, 2011Publication date: May 12, 2011Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Denise L. Faustman, Douglas E. Burger
-
Patent number: 7867765Abstract: The invention relates to methods of isolating white blood cells (WBCs) from a sample, e.g., whole blood, using magnetic particles that specifically bind to WBCs and a series of specific steps and conditions. The methods can include one or more of decreasing the viscosity of the sample prior to WBC isolation, agitating the sample at specified frequencies, and/or using a sample container arranged such that all of the sample is placed in close proximity (e.g., within 5, 2, 1, or 0.5 mm) to the source of the magnetic field. The new methods provide for isolation of WBC preparations with high yield, purity, and viability. The methods are designed for compatibility with automation protocols for rapid processing of multiple samples.Type: GrantFiled: December 28, 2006Date of Patent: January 11, 2011Assignee: The General Hospital CorporationInventors: Denise L. Faustman, Douglas E. Burger
-
Publication number: 20100068177Abstract: The invention features methods for increasing or maintaining the number of functional cells of a predetermined type in a mammal (e.g., a human patient), for example, the insulin producing cells of the pancreas, liver cells, spleen cells, or bone cells, that has injured or damaged cells of the predetermined type or is deficient in cells of the predetermined type.Type: ApplicationFiled: August 28, 2009Publication date: March 18, 2010Applicant: The General Hospital CorporationInventor: Denise L. Faustman
-
Patent number: 7628988Abstract: The invention features methods for increasing or maintaining the number of functional cells of a predetermined type, for example, insulin producing cells of the pancreas, blood cells, spleen cells, brain cells, heart cells, vascular tissue cells, cells of the bile duct, or skin cells, in a mammal (e.g., a human patient) that has injured or damaged cells of the predetermined type.Type: GrantFiled: February 5, 2003Date of Patent: December 8, 2009Assignee: The General Hospital CorporationInventor: Denise L. Faustman
-
Patent number: 7582313Abstract: The invention features methods for increasing or maintaining the number of functional cells of a predetermined type in a mammal (e.g., a human patient), for example, the insulin producing cells of the pancreas, liver cells, spleen cells, or bone cells, that has injured or damaged cells of the predetermined type or is deficient in cells of the predetermined type.Type: GrantFiled: October 31, 2003Date of Patent: September 1, 2009Assignee: The General Hospital CorporationInventor: Denise L. Faustman
-
Patent number: 7537756Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: GrantFiled: May 19, 2005Date of Patent: May 26, 2009Assignee: The General Hospital CorporationInventors: Joel E. Habener, Hendrik Zulewski, Elizabeth J. Abraham, Mario Vallejo, Denise L. Faustman, Melissa K. Thomas
-
Patent number: 7485293Abstract: A method for inhibiting rejection of tissues transplanted into a mammalian host is disclosed. Treatment of the tissues with an enzyme or combination of enzyme, particularly papain, to eliminate cell surface structures necessary for recognition by the host's immune system, particularly MHC Class I molecules, avoids or reduces the attack of the host's immune system on the transplanted tissues. Tissues that are enzymatically shaved of MHC Class I antigens and/or other critical adhesion molecules can be rendered at least temporarily resistant or immune to attack by cytolytic T lymphocytes, helper T lymphocytes, antibodies, or other effector cells of a host's immune system, thereby enhancing the survivability of the tissues in the host after transplant.Type: GrantFiled: February 18, 2000Date of Patent: February 3, 2009Inventor: Denise L. Faustman
-
Patent number: 7438902Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: GrantFiled: November 9, 2004Date of Patent: October 21, 2008Assignee: The General Hospital CorporationInventors: Joel E. Habener, Henryk Zulewski, Elizabeth J. Abraham, Mario Vallejo, Denise L. Faustman, Melissa K. Thomas
-
Publication number: 20080102054Abstract: The invention features a therapeutic composition containing mammalian, preferably human, post-fetal, AGM cells in a pharmaceutically acceptable carrier. The compositions of the invention can be administered to treat patients suffering from autoimmune diseases, to treat patients in need of organ or cell regeneration, and to treat patients in need of immune, especially hematopoietic, reconstitution.Type: ApplicationFiled: January 18, 2006Publication date: May 1, 2008Inventor: Denise L. Faustman
-
Patent number: 6923959Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: GrantFiled: May 2, 2002Date of Patent: August 2, 2005Assignee: The General Hospital CorporationInventors: Joel F. Habener, Henryk Zulewski, Elizabeth J. Abraham, Mario Vallejo, Denise L. Faustman, Melissa K. Thomas
-
Patent number: 6866843Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: GrantFiled: December 6, 2000Date of Patent: March 15, 2005Assignee: Viacell, Inc.Inventors: Joel F. Habener, Henryk Zulewski, Elizabeth Abraham, Mario Vallejo, Denise L. Faustman, Melissa K. Thomas
-
Patent number: 6773705Abstract: The invention provides a method of detecting autoimmune disease in a mammal, comprising providing a biological sample from a mammal and detecting proteasome activity, wherein a reduction in proteasome activity from a basal state is indicative of autoimmune disease. In addition, the invention encompasses a method of treating an autoimmune disease in a mammal, comprising administering to a mammal suspected of suffering from an autoimmune disease an agent which restores NF&kgr;B activity in an amount and for a time sufficient to result in normal NF&kgr;B activity in the mammal.Type: GrantFiled: February 26, 1999Date of Patent: August 10, 2004Assignee: General Hospital CorporationInventors: Denise L. Faustman, Takuma Hayashi
-
Publication number: 20040031066Abstract: Nonobese Diabetic Mice (NOD mice) that do not develop diabetes may be bred to produce F1 offspring that develop a condition that closely mimics rheumatoid arthritis (RA) in humans. The RA-like disease in the F1 mice, designated NOD-RA mice, is similar to human RA in clinical, radiological, histological and serological characteristics. The parents (F0) and their progeny (F1) are not diabetic and never develop hyperglycemia, and the parental mice (F0) do not themselves exhibit any symptoms of the RA-like condition that afflicts some of their progeny. The incidence, penetrance, gender domination, progression, and lifelong exacerbation of symptoms after pregnancy shown in the RA-like condition afflicting NOD-RA mice are all comparable to phenomena observed in the human disease. The NOD-RA mice provide a new spontaneous model of human RA that will be useful for studying rheumatoid arthristis and testing new drugs and reagents for treating or diagnosing the disease.Type: ApplicationFiled: July 16, 2002Publication date: February 12, 2004Inventors: Denise L. Faustman, Takuma Hayashi
-
Patent number: 6617171Abstract: The invention provides a method of detecting autoimmune disease in a mammal, comprising providing a biological sample from a mammal and detecting proteasome activity, wherein a reduction in proteasome activity from a basal state is indicative of autoimmune disease. In addition, the invention encompasses a method of treating an autoimmune disease in a mammal, comprising administering to a mammal suspected of suffering from an autoimmune disease an agent which restores NF&kgr;B activity in an amount and for a time sufficient to result in normal NF&kgr;B activity in the mammal.Type: GrantFiled: February 27, 1998Date of Patent: September 9, 2003Assignee: The General Hospital CorporationInventors: Denise L. Faustman, Takuma Hayashi
-
Publication number: 20030031657Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: ApplicationFiled: May 2, 2002Publication date: February 13, 2003Applicant: Massachusetts General HospitalInventors: Joel F. Habener, Henryk Zulewski, Elizabeth J. Abraham, Mario Vallejo, Denise L. Faustman, Melissa K. Thomas
-
Publication number: 20030005469Abstract: Nonobese Diabetic Mice (NOD mice) that do not develop diabetes may be bred to produce F1 offspring that develop a condition that closely mimics rheumatoid arthritis (RA) in humans. The RA-like disease in the F1 mice, designated NOD-RA mice, is similar to human RA in clinical, radiological, histological and serological characteristics. The parents (F0) and their progeny (F1) are not diabetic and never develop hyperglycemia, and the parental mice (F0) do not themselves exhibit any symptoms of the RA-like condition that afflicts some of their progeny. The incidence, penetrance, gender domination, progression, and lifelong exacerbation of symptoms after pregnancy shown in the RA-like condition afflicting NOD-RA mice are all comparable to phenomena observed in the human disease. The NOD-RA mice provide a new spontaneous model of human RA that will be useful for studying rheumatoid arthristis and testing new drugs and reagents for treating or diagnosing the disease.Type: ApplicationFiled: July 16, 2002Publication date: January 2, 2003Inventors: Denise L. Faustman, Takuma Hayashi
-
Patent number: 6414218Abstract: Nonobese Diabetic Mice (NOD mice) that do not develop diabetes may be bred to produce F1 offspring that develop a condition that closely mimics rheumatoid arthritis (RA) in humans. The RA-like disease in the F1 mice, designated NOD-RA mice, is similar to human RA in clinical, radiological, histological and serological characteristics. The parents (F0) and their progeny (F1) are not diabetic and never develop hyperglycemia, and the parental mice (F0) do not themselves exhibit any symptoms of the RA-like condition that afflicts some of their progeny. The incidence, penetrance, gender domination, progression, and lifelong exacerbation of symptoms after pregnancy shown in the RA-like condition afflicting NOD-RA mice are all comparable to phenomena observed in the human disease. The NOD-RA mice provide a new spontaneous model of human RA that will be useful for studying rheumatoid arthritis and testing new drugs and reagents for treating or diagnosing the disease.Type: GrantFiled: January 18, 2000Date of Patent: July 2, 2002Assignee: The General Hospital CorporationInventors: Denise L. Faustman, Takuma Hayashi